VD
Dutoit Vallotton, Valérie
Affiliation entities
Research groups
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | 2024 | 79 | 61 | |||
A novel mitochondrial pyruvate carrier inhibitor drives stem cell-like memory CAR T cell generation and enhances antitumor efficacy | Molecular therapy. Oncology | 2024 | 30 | 55 | |||
Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro | Radiotherapy and oncology | 2024 | 54 | 10 | |||
Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages | Cell communication and signaling | 2024 | 59 | 15 | |||
Neoantigen-specific T-cell response after donor lymphocyte infusion associates with favorable outcome in a patient with i(12p) germ cell tumor, acute leukemia and sarcoma of the same clonal origin | Haematologica | 2024 | 53 | 14 | |||
Promises and challenges of predictive blood biomarkers for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy | Cells | 2023 | 80 | 42 | |||
PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma | 2023 | 117 | 265 | ||||
Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | 2023 | 245 | 46 | |||
Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer | BMC cancer | 2022 | 178 | 50 | |||
Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | 2022 | 161 | 73 | |||
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma | Frontiers in Immunology | 2021 | 390 | 235 | |||
Emerging Trends for Radio-Immunotherapy in Rectal Cancer | Cancers | 2021 | 29 | 21 | |||
Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread | Neurology Genetics | 2021 | 282 | 57 | |||
Metataxonomic and Metabolic Impact of Fecal Microbiota Transplantation From Patients With Pancreatic Cancer Into Germ-Free Mice: A Pilot Study | Frontiers in cellular and infection microbiology | 2021 | 247 | 87 | |||
Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells | Communications Biology | 2021 | 288 | 179 | |||
Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors | International Journal of Molecular Sciences | 2020 | 219 | 154 | |||
An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | 2020 | 427 | 260 | |||
Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma | OncoImmunology | 2020 | 333 | 248 | |||
Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients | Frontiers in Oncology | 2020 | 276 | 97 | |||
Stratégies de vaccination thérapeutique dans le glioblastome | Medecine Sciences | 2020 | 174 | 262 | |||
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review | Journal for immunotherapy of cancer | 2020 | 145 | 149 | |||
Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma | Molecular and Cellular Proteomics | 2019 | 381 | 2 | |||
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | 2019 | 747 | 360 | |||
Current strategies for vaccination in glioblastoma | Current Opinion in Oncology | 2019 | 365 | 5 | |||
Peptides as cancer vaccines | Current Opinion in Pharmacology | 2019 | 371 | 4 | |||
Actively personalized vaccination trial for newly diagnosed glioblastoma | Nature | 2019 | 505 | 12 | |||
Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients | Cancers | 2019 | 328 | 155 | |||
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma | Molecular and Cellular Proteomics | 2018 | 394 | 2 | |||
Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | 2018 | 604 | 270 | |||
First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies | OncoImmunology | 2017 | 581 | 9 | |||
Immunothérapie des gliomes : illusion ou espoir ? | Bulletin du cancer | 2017 | 377 | 0 | |||
ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells | EMBO Journal | 2017 | 561 | 10 | |||
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma | Cancer Cell | 2017 | 466 | 5 | |||
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Frontiers in Oncology | 2016 | 462 | 384 | |||
Human tissue engineering allows the identification of active miRNA regulators of glioblastoma aggressiveness | Biomaterials | 2016 | 516 | 5 | |||
Ipilimumab-related hypophysitis may precede severe CNS immune attack | Annals of Oncology | 2016 | 432 | 0 | |||
Identification of glioma-associated antigens for brain tumor immunotherapy | 2015 | 615 | 463 | ||||
Immunotherapy of Brain Tumors | Progress in tumor research | 2015 | 530 | 0 | |||
Immunotherapy for glioma: from illusion to realistic prospects? | American Society of Clinical Oncology educational book | 2014 | 1,198 | 559 | |||
Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response | International journal of cancer | 2014 | 685 | 389 | |||
Extrachromosomal driver mutations in glioblastoma and low-grade glioma | Nature communications | 2014 | 696 | 184 | |||
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) | European urology | 2013 | 554 | 0 | |||
The relationship between brain tumor cell invasion of engineered neural tissues and in vivo features of glioblastoma | Biomaterials | 2013 | 661 | 6 | |||
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy | Brain | 2012 | 641 | 1,277 |